Compare IDEXX Laboratories, Inc. (IDXX) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Starbucks Corp — how do they compare? IDEXX Laboratories, Inc. trades at $572.01 (market cap $44.95B), while Starbucks Corp trades at $108.65 (market cap $123.68B). The key difference: Starbucks Corp is far larger — about 2.8× IDEXX Laboratories, Inc.'s market cap, and Starbucks Corp pays a 2.29% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | SBUX | |
|---|---|---|
Market Cap | $44.95B | $123.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $108.49 |
52-Week Low | $526.44 | $78.46 |
Enterprise Value | $45.85B | $142.50B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.
The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
